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Abstract 
 
The aim of this thesis was to evaluate patients with symptoms suggestive of acute coronary syndrome with 
regard to early diagnosis and prognosis by the use of high sensitive cardiac troponin T and a risk score: 
 
In paper I, the early diagnostic value of high sensitive cardiac troponin T (hs-cTnT) was compared with 
conventional cardiac troponin assays in 233 patients with symptoms suggestive of acute coronary syndrome 
(ACS). When acute myocardial infarction (MI) was defined according to conventional cardiac troponins and the 
lowest level with a coefficient of variation (CV) ≤ 10% for each method was used as decision limit, hs-cTnT 
had a higher sensitivity than the conventional cardiac troponins. When acute MI was defined according to hs-
cTnT, hs-cTnT performed better than the conventional cardiac troponins at different decision limits and had the 
largest Area Under Curve (AUC) in ROC analysis. 
 
In paper II, the prognostic value of hs-cTnT was compared with conventional cardiac troponin assays in 231 
patients with symptoms suggestive of ACS. When the lowest level with a CV ≤ 10% for each method was used 
as decision limit, hs-cTnT identified more high-risk patients. After adjusting for differences in clinical baseline 
characteristics, hs-cTnT and N-terminal pro B-type natriuretic peptide (NT-proBNP)  were independently 
associated with outcome. By combining hs-cTnT and NT-proBNP, patients could be divided into low-, 
intermediate- and high-risk groups.  
 
In paper III, HEART score was validated in 410 consecutive patients with chest pain. Of 247 (60.2 %) patients 
in HEART score 0-3, one patient (0.4%) had a combined endpoint. Of 144 (35.1 %) patients in heart score 4-6, 
19 (13.2 %) patients had a combined endpoint. Of 19 (4.6%) patients in HEART score 7-10, 10 (52.6 %) 
patients had a combined endpoint. Of all admitted patients, 34.3 % had a HEART score 0-3. 
 
In paper IV: 48,594 patients admitted because of symptoms suggestive of ACS were included to examine the 
effects of introducing hs-cTnT into clinical practice. 25 % had hs-cTnT < 14 ng/L (group 1), 22 % had hs-cTnT 
14-49 ng/L (group 2) and 53 % had hs-cTnT ≥ 50 ng/L (group 3). From group 1 to 3, there was a stepwise 
increase with regard to proportion of patients with significant coronary stenoses, left ventricular systolic 
dysfunction and death during follow-up. Thus, the introduction of hs-cTnT has led to a large proportion of 
patients with minor cardiac troponin elevation (14-49 ng/L). The majority with minor elevation do not have 
myocardial infarction but are still at high risk. When dividing patients into 20 groups according to hs-cTnT 
level, the adjusted mortality started to increase at hs-cTnT level of 14 ng/L. 
 
Conclusion: hs-cTnT improves early diagnosis and risk stratification compared with conventional cardiac 
troponin assays. An excellent risk prediction can be achieved by combining hs-cTnT and NT-proBNP in an 
easily used algorithm. The introduction of hs-cTnT has resulted in identification of a large population with only 
minor elevation of hs-cTnT (14-49 ng/L) but are still at high risk.  HEART score may be a useful tool for 
evaluation of chest pain patients and identify a low-risk group in which admission and further investigations 
may not be necessary.   
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